









































































Flu（Fludara div：30mg/ ㎡：Day-7～ -3）＋ BU
（Busulfan：0.8㎎ / ㎏ ×4/day：Day-7 ～‐4）
＋ L-PAM(Melphalan：40㎎ / ㎡：Day-2) ＋ ATG






























































































ン療法（Day １リツキシマブ：375㎎ / ㎡，day





なかったが，Grade ４（National Cancer Institute 






























図７　治療経過：R(Rituximab), THP(Pirarubicin), C(Cyclophosphamide), O(Vincristine), P(Prednisolone),
 E(Etoposide), B(Bendamustine)
表１　PTLD の分類















HL Hodgkin 細胞　RS 細胞 50% で陽性
PTLD： post-transplant lymphoproliferative disorders
HL： Hodgkin lymphoma
EBV： EBvirus








































































いる．初発未治療 Indolent lymphoma を対象と






難治 DLBCL に対する second line 以降での治療
法として，リツキシマブ併用ベンダムスチン
療法は，Ohmachi ら11）は，全奏効率 62.7%，寛












とができ、難治性 monomorphic PTLD に対して
リツキシマブ併用ベンダムスチン療法が有効で
ある可能性が示唆された．
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Response to combination therapy with rituximab  
and bendamustine for intestinal monomorphic PTLD
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ABSTRACT   Post-transplantation lymphoproliferative disorder (PTLD) occurs as a result 
of the use of immunosuppressants following hematopoietic stem cell transplantation, which 
causes the emergence of abnormal lymphocytes owing to the decline in T-cell function and 
the proliferation of plasma cells. It is thus one of the most fatal complications and the biggest 
concern for transplantation cases. PTLD is classified into 4 categories, and monomorphic PTLD 
takes the form of a malignant lymphoma. Immunosuppressant dose reduction, rituximab (R) 
monotherapy, and R-CHOP therapy are used to treat monomorphic PTLD, but the prognosis 
is poor for these forms of treatment. This report describes the experience of a patient with 
refractory PTLD who went into remission after responding to combination therapy with rituximab 
and bendamustine. A 50-year-old man underwent cord blood transplantation because of a 
myelodysplastic syndrome. Tacrolimus was used for GVHD prevention. After transplantation, 
symptoms of GVHD of the gastrointestinal tract developed, and during treatment using 
prednisolone, symptoms of monomorphic PTLD (diffuse large B-cell lymphoma) emerged. Once 
immunosuppressant use was discontinued, the patient underwent R monotherapy and R-CHOP-
like treatment, but the response was poor. The treatment was then changed to combination 
therapy with rituximab and bendamustine; after 4 courses of treatment, gastrointestinal 
endoscopy revealed that the pathological abnormality had disappeared, and a complete 
response was confirmed. One year has passed since the completion of treatment, and at 
present, the patient’s symptoms have not worsened, suggesting that combination therapy with 
rituximab and bendamustine is effective for treating monomorphic PTLD.
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